Skip Navigation

European Heart Journal 1990 11(11):1006-1010;
Copyright © 1990 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by HERVE, C.
Right arrow Articles by LEROUX, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HERVE, C.
Right arrow Articles by LEROUX, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 The European Society of Cardiology

Cost-benefit analysis of thrombolytic therapy

C. HERVE*,, D. CASTIEL**, M. GAILLARD***, R. BOISVERT*** and V. LEROUX***

*CHU Necker Paris
**Facultè de Sciences Economiques Saint-Hilaire
***CHU Mondor, Crèteil France

Received 25 September 1989; revised 2 January 1990; .

Correspondence: C. Herve, CHU Necker, 156 rue de Vaugirard, 75 730 Paris Cedex, France.

Abstract

Thrombolysis is a new treatment for myocardial infarct patients. 162 such patients were studied: 62 received thrombolytic treatment and 100 a classical therapy. For cost-benefit analysis, all patients were followed for at least 1 year and received an identical questionnaire to assess the costs induced by this disease.

At 1 year, 10% had died in the two groups. Patients who received thrombolytic treatment had a hospital stay 2 days longer, on average, but were readmitted for shorter periods (10.3 days less). Thrombolysis was more expensive (£10550 vs £8998. Therefore, it is necessary to invest £150 to reduce rehospitalization time by 1 day.

Benefits were almost 31% greater for thrombolysis patients and the cost-benefit ratio was about 0.7. Thus the monetary benefits, initially rather negative, became positive at the end ofthe first year.

Key Words: Cost-benefit analysis • myocardial infarction • thrombolysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.